Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2022-04-27 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association (公司章程). It includes specific amendments to the company's bylaws, governance structure, shareholder rights, board responsibilities, and other corporate governance matters. The document references compliance with regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. It is not a financial report, earnings release, or a simple announcement of a report publication. Instead, it focuses on governance rules and company internal regulations. Therefore, the document fits best under the category of Governance Information (CGR). The document length and detail confirm it is the actual governance document content, not just an announcement or summary.
2022-04-27 Chinese
亚宝药业集团股份有限公司2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (quarterly). The presence of comprehensive financial statements and analysis confirms it is an Interim / Quarterly Report. There is no indication that this is an announcement or a certification document, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-27 Chinese
亚宝药业集团股份有限公司第八届董事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 7th meeting of the 8th Board of Directors of 亚宝药业集团股份有限公司. It includes approvals of the 2021 annual report, board work report, general manager report, independent directors' report, financial statements, profit distribution plan, internal control evaluation report, social responsibility report, and the 2022 Q1 report. However, the document itself does not contain the full reports or financial data but refers to these reports being published separately on the Shanghai Stock Exchange website. The document also includes voting results and mentions that some items will be submitted to the 2021 annual general meeting for approval. Given the nature of the document as a board meeting resolution announcement summarizing approvals and referring to full reports elsewhere, it fits best as a Regulatory Filing (RNS) rather than the reports themselves or a voting results announcement. The document length is under 5,000 characters and primarily serves as an announcement of board decisions and references to other filings.
2022-04-27 Chinese
亚宝药业集团股份有限公司2021年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It is issued by a certified public accountant firm (致同会计师事务所) and addresses the shareholders of 亚宝药业集团股份有限公司 for the fiscal year 2021. The content includes detailed audit opinions, basis for audit opinions, key audit matters such as goodwill impairment testing and accounts receivable credit loss measurement, responsibilities of management and auditors, and detailed financial statements including balance sheets and notes. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories.
2022-04-27 Chinese
亚宝药业集团股份有限公司2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2021 Annual Report Summary" of 亚宝药业集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2021, including profit distribution plans, company business overview, industry policy impacts, and detailed accounting data over multiple years and quarters. The presence of audited financial figures and comprehensive business and financial information aligns with the characteristics of an Annual Report (10-K). The document length is 8251 characters, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it is classified as an Annual Report (10-K). FY 2021
2022-04-27 Chinese
亚宝药业集团股份有限公司章程（2022年4月修订）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 亚宝药业集团股份有限公司 (Yabao Pharmaceutical Group Co., Ltd.). It includes comprehensive provisions on company organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. There is no indication of financial statements, audit reports, earnings data, or meeting presentations. The content is focused on internal rules and governance structure rather than financial performance or announcements. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not a brief announcement or a report publication notice.
2022-04-27 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.